Beam Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Beam Therapeutics Inc. is a clinical-stage biotechnology company pioneering the field of precision genetic medicines through base editing. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company's proprietary platform enables single-base genomic corrections without causing double-stranded DNA breaks, offering a highly differentiated approach to gene editing. Beam's pipeline is organized across three primary disease portfolios: hematology (led by BEAM-101/risto-cel for sickle cell disease), genetic diseases (led by BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-304 for phenylketonuria), and immunology/oncology.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the clinical development of ristoglogene autogetemcel (risto-cel, formerly BEAM-101) for severe sickle cell disease, aiming for a BLA submission as early as year-end 2026.
Expected impact: Establishes Beam's first commercial product and validates its ex vivo base editing platform.
Advancing BEAM-302, an in vivo liver-targeting base editor, into a global pivotal cohort of approximately 50 patients to support an accelerated approval pathway based on AAT biomarkers.
Expected impact: Provides a potential first-in-class and best-in-class treatment for both lung and liver manifestations of AATD.
Utilizing an innovative platform-based development approach to evaluate multiple mutation-specific base editors under a single clinical program, starting with the R408W mutation.
Expected impact: Demonstrates a scalable development pathway that can streamline regulatory reviews for rare genetic diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to integrate Guide's proprietary lipid nanoparticle (LNP) screening platform, strengthening Beam's in vivo delivery capabilities to the liver and other tissues.
Financial impact: Bolstered intellectual property and delivery technology, supporting subsequent in vivo programs like BEAM-302 and BEAM-304.
Strategic Partnerships
High
Terms: Beam received a $300 million upfront payment in January 2022 and is eligible for up to $1.05 billion in milestone payments. In December 2025, Pfizer exercised its option for a liver-targeted candidate, triggering potential future milestones and giving Beam a 35% co-development/co-commercialization opt-in right.
Medium
Terms: Five-year collaboration signed in June 2021. Beam received $75 million in upfront and near-term milestones, with eligibility for future development, regulatory, and sales milestones, plus royalties. Beam holds a 50-50 U.S. co-development/co-commercialization option on one program.
Medium
Terms: Signed in October 2021. Sana paid Beam a $50 million upfront payment for non-exclusive commercial rights to Beam's CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs, with eligibility for milestones and royalties.
High
Terms: In October 2023, Eli Lilly acquired Beam's opt-in rights to Verve Therapeutics' cardiovascular programs. Beam received a $200 million upfront payment and a $50 million equity investment, and is eligible for up to $350 million in future development-stage payments.